Geographic Atrophy Secondary to Age-related Macular DegenerationPhase 3GALENCT04770545
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
A Phase 3 study testing PEGCETACOPLAN (APL-2) in people with Geographic Atrophy Secondary to Age-related Macular Degeneration, run by Apellis Pharmaceuticals, Inc. at 175 sites in 15 countries.
Trial summary
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of… Read more about this study
- Who is it for?
- Ages 60 years and older
- Conditions the study is for
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- What is being tested?
- PEGCETACOPLAN (APL-2)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 792 participants
- Where
- 175 sitesin 15 countries
- Study dates
- 4 Mar 2021to 5 Sep 2025
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Ocular-specific inclusion criteria apply to the study eye only.
- Subjects must have participated in APL2-103 (NCT03777332) or completed the treatment at Month 24 of either APL2-303 (Derby, NCT03525613) or APL2-304 (Oaks, NCT03525600).
- For subjects who participated in either the 303 or 304 studies, the condition listed below must also be met for participating in this study.
- Subjects who did not fully stop study drug treatment, but missed the visit at Month 24, can also participate in the study. However, to participate, subjects must be seen within 60 days from the last day of the period allowed for the 24 months visit in the previous study.
- The eyes of subjects must have transparency to permit visualization of parts inside the eye such as the retina and subjects must be able to look steadily at a provided target allowing the doctor to get good quality pictures from the eye.
Show all 11Show fewer
- Female subjects must be:
- Women that cannot have children, or
- Women who can have children must have a negative result of a blood pregnancy test on the first day of the study visit and agree to use ways to avoid pregnancy during the study and 90 days after the last dose of the study medication.
- Males with female partners who can get pregnant must also agree to use ways to avoid pregnancy and agree not to donate sperm while in the study or until 90 days after administering the last dose of the study medication.
- Agree to participate in the study by signing the consent document providing information about the study; and take part in all tests and assessments as required.
Who cannot join
- Subjects cannot take part in the study if the eye that will be treated during the study currently meets any of the following conditions:
- Participants in APL2 303/304 studies who fully stopped study drug treatment before the visit in month 24 but remain in the study to observe the study medication's safety. Those subjects who temporarily paused study drug treatment are still eligible to participate.
- If, according to your doctor you currently have any disease affecting your eyes that could interfere with your vision, including diseases that affect your retina or macula (the center of the back of your eyes). And, if according to your doctor, the disease in your eyes is benign and does not interfere with the study (e.g. diseases that affects the periphery of the retina), you are also eligible to take part in the study.
- If, according to your doctor you currently have any inflammation/infection in or around your eyes that could prohibit you from receiving an injection inside your eyes.
- If, according to your doctor, any current disease that could directly interfere in your participation in the study or that could make it difficult for you to come to the scheduled visits during the next three years over the next 36 months.
- If you have known allergies to fluorescein sodium, a solution that is injected into your body for eye testing; or to pegcetacoplan (the study drug) or any inactive substances in pegcetacoplan solution.
- If you currently are pregnant, breastfeed or have a positive pregnancy test.
Trial locations and contacts
175 sites in 15 countries.
175 sites in 15 countries
United States99 sites
Vision Research Center Eye Associates of NM
Albuquerque, New Mexico, 87109
Michigan Medicine Kellogg Eye Center
Ann Arbor, Michigan, 48105
Western Carolina Retinal Associates
Asheville, North Carolina, 28803
Southeast Retina Center, PC
Augusta, Georgia, 30909
Retina Research Center PLLC
Austin, Texas, 78750
California Retina Consultants
Bakersfield, California, 93309
The Retina Care Center
Baltimore, Maryland, 21209
Elman Retina Group
Baltimore, Maryland, 21236
Brown Retina Institute
Bellaire, Texas, 77401
Vitreoretinal Associates of Washington
Bellevue, Washington, 98004
Mid Atlantic Retina
Bethlehem, Pennsylvania, 18107
Retina Center of NJ, LLC
Bloomfield, New Jersey, 07003
Gailey Eye Clinic Retina Center
Bloomington, Illinois, 61704
Ophthalmic Consultants of Boston
Boston, Massachusetts, 02114
Tufts Medical Center
Boston, Massachusetts, 02116
Florida Eye Microsurgical Institute, Inc.
Boynton Beach, Florida, 33426
Retinal Diagnostic Center
Campbell, California, 95508
Charlotte Eye Ear Nose and Throat Associates, PS
Charlotte, North Carolina, 28210
University of Virginia
Charlottesville, Virginia, 22903
The Retina Group of Washington
Chevy Chase, Maryland, 20815
Northwestern Feinberg School of Medicine
Chicago, Illinois, 60611
Rush University Medical Center
Chicago, Illinois, 60612
Blue Ocean Clinical Research
Clearwater, Florida, 33761
Retina Associates of Cleveland, Inc.
Cleveland, Ohio, 44122
Retina Associates of Cleveland
Cleveland, Ohio, 44130
Cleveland Clinic Cole Eye Institute
Cleveland, Ohio, 44195
The Ohio State University
Columbus, Ohio, 43212
Texas Retina Associates
Dallas, Texas, 75231
Danbury Eye Physicians & Surgeons, PC
Danbury, Connecticut, 06810
Southwest Retina Research Center, LLC
Durango, Colorado, 81301
Duke University, Duke Eye Center
Durham, North Carolina, 27710
Retina Vitreous Center, PLLC
Edmond, Oklahoma, 73013
The Retina Partners
Encino, California, 91436
Oregon Retina LLP
Eugene, Oregon, 97405
The Retina Group of Washington
Fairfax, Virginia, 22031
Emerson Clinical Research Institute
Falls Church, Virginia, 22046
Pinnacle Research Institute
Fort Lauderdale, Florida, 33309
Retina Health Center
Fort Myers, Florida, 33907
National Ophthalmic Research Institute
Fort Myers, Florida, 33912
Retina Consultants of Orange County
Fullerton, California, 92835
Charles Retina Institute
Germantown, Tennessee, 38138
Associated Retinal Consultants, PC
Grand Rapids, Michigan, 49546
Long Island Vitreoretinal Consultants
Great Neck, New York, 11021
Cumberland Valley Retina Center
Hagerstown, Maryland, 21740
Mid Atlantic Retina Specialist
Hagerstown, Maryland, 21740
Graystone Eye
Hickory, North Carolina, 28602
Houston Eye Associates
Houston, Texas, 77025
Retina Consultants of Houston, PA
Houston, Texas, 77030
Atlantis Eyecare
Huntington Beach, California, 92647
Midwest Eye Institute
Indianapolis, Indiana, 46290
Jacobs Retina Center, UCSD
La Jolla, California, 92093
Retina and Vitreous Associates of Kentucky, PSC dba Retina Associates of Kentucky
Lexington, Kentucky, 40509
Doheny Eye Center UCLA
Los Angeles, California, 90033
Retina Health Center
Madison, Wisconsin, 53705
Retina-Vitreous Associates Medical Group
Madison, Wisconsin, 53705
Georgia Retina, PC
Marietta, Georgia, 30060
Valley Retina Institute
McAllen, Texas, 78503
Bascom Palmer Eye Institute
Miami, Florida, 33136
Vitreoretinal Surgery
Minneapolis, Minnesota, 55435
Retina Vitreous Consultants
Monroeville, Pennsylvania, 15146
Northern California Retina Vitreous Associates
Mountain View, California, 94040
Retina Associates of Utah, PC
Murray, Utah, 84107
Bascom Palmer Eye Institute at Naples
Naples, Florida, 34103
Tennessee Retina, PC
Nashville, Tennessee, 78503
Vitreous Retina Macula Consultants of New York
New York, New York, 10022
Ophthalmic Consultants of Long Island
Oceanside, New York, 11572
Palm Beach Gardens
Palm Beach Gardens, Florida, 33418
Retina Institute of California Medical Group
Palm Desert, California, 92260
Byers Eye Institute, Stanford University
Palo Alto, California, 94303
Retina Specialty Institute
Pensacola, Florida, 32503
Mid Atlantic Retina
Philadelphia, Pennsylvania, 19006
Mid Atlantic Retina
Philadelphia, Pennsylvania, 19107
Retinal Research Institute, LLC
Phoenix, Arizona, 85014
Associated Retina Consultants, Ltd.
Phoenix, Arizona, 85020
Eye Associates of Pinellas
Pinellas Park, Florida, 33782
Retina Northwest, PC
Portland, Oregon, 97221
Eye Health Northwest
Portland, Oregon, 97225
Retina Consultants San Diego
Poway, California, 92064
Black Hills Regional Eye Institute
Rapid City, South Dakota, 57701
Sierra Eye Associates
Reno, Nevada, 89503
University of Utah - John A. Moran Center
Salt Lake City, Utah, 84312
Medical Center Ophthalmology Associates
San Antonio, Texas, 78240
Retina Associates of South Texas
San Antonio, Texas, 78240
Orange County Retina Medical Group
Santa Ana, California, 92705
California Retina Consultants
Santa Barbara, California, 93103
Spokane Eye Clinical Research
Spokane, Washington, 99204
New England Retina Consultants, PC
Springfield, Massachusetts, 01107
East Florida Eye Institute
Stuart, Florida, 34994
Retina Associates of Florida
Tampa, Florida, 33609
University of South Florida
Tampa, Florida, 33612
NJ Retina
Teaneck, New Jersey, 07666
Retina Consultants of Houston
The Woodlands, Texas, 77384
NJ Retina
Toms River, New Jersey, 08755
Associated Retinal Consultants, PC
Traverse City, Michigan, 49686
Bay Area Retina Associates
Walnut Creek, California, 94598
Retina Group of New England - New London
Waterford, Connecticut, 06835
AIO Visionary Eye Care
West Mifflin, Pennsylvania, 15122
Center for Retina and Macular Disease
Winter Haven, Florida, 33880
Retina Associates of Cleveland, Inc.
Youngstown, Ohio, 44505
France14 sites
CHU de Bordeaux
Bordeaux, 33076
Centre Hospitalier Intercommunal de Creteil
Créteil, 94010
CHU Dijon
Dijon, 21 079
Clinique du Val d'Ouest
Écully, 69130
Hopital de la Croix-Rousse
Lyon, 69004
Centre monticelli Paradis
Marseille, 13008
CHU de Nantes - Hotel Dieu
Nantes, 44093
Centre Ophtalmol de l Odeon
Paris, 75006
Hopital Lariboisiere
Paris, 75010
CHNO des Quinze-Vingts
Paris, 75012
Centre Ophtalmo. Image/Laser
Paris, 75015
Centre ophtalmologique Saint-Exupery
Saint-Cyr-sur-Loire, Lyon, 37540
Maison Rouge Ophthalmologic Center
Strasbourg, 67000
CHU de Strasbourg Hopital Civil
Strasbourg, 67091
Germany12 sites
Universitats-Augenklinik Bonn
Bonn, 53127
Uniklinik Koln
Cologne, 50937
University Opthalmology Clinic
Freiburg im Breisgau, 79106
Uni-medizin Gottingen Augenklinik 3.B1.261
Göttingen, 37075
Universitatsklinikum Schleswig-Holstein
Lübeck, 23538
Klinikum der Stadt Ludwigshafen gGmbH
Ludwigshafen, 67063
Augenklinik der LMU Munchen
München, 80336
Klinikum rechts der Isar
München, 81675
Augenzentrum am St. Franziskus-Hospital
Münster, 48145
Universitatsklinikum Regensburg
Münster, 48145
Universitatsklinikum Munster
Münster, 48149
STZ Eyetrial
Tübingen, 72076
Argentina8 sites
Diagnostico Ocular
Buenos Aires, 1425
Organizacion Medica de Investigacion (OMI)
Buenos Aires, C1015 ABO
Fundacion Zambrano
Buenos Aires, C1023 AAQ
Centro Oftalmologico Dr. Charles S.A.
Buenos Aires, C1116ABA
Instituto Oftalmologico de Cordoba
Córdoba, 5000
OFTAR
Mendoza, 5500
Microcirujia Ocular Rosario
Rosario, 2000
Oftalmologos Especialistas
Santa Fe, S2000
Australia8 sites
Centre for Eye Research Australia
East Melbourne, Victoria, 3002
Retina and Eye Consultantss
Hurstville, 2220
Lions Eye Institute
Nedlands, 6009
Marsden Eye Specialist
Parramatta, New South Wales, 2150
Strathfield Retina Clinic
Strathfield, New South Wales, 2135
Sydney Retina
Sydney, New South Wales, 2000
The Ashley Centre
Westmead, New South Wales, 2145
Save Sight Institute
Westmead, 2145
United Kingdom8 sites
Bristol Eye Hospital
Bristol, BS1 2LX
Huddersfield Royal Infirmary
Huddersfield, West Yorkshire, HD3 3EA
St James's University Hospital
Leeds, West Yorkshire, LS9 7TF
Royal Liverpool University Hospital
Liverpool, L7 8XP
Kings College Hospital NHS Trust
London, SE5 9RS
London Vision Clinic
London, W1G 7LA
Oxford Eye Hospital
Oxford, OX3 9DU
Sunderland Eye Infirmary
Sunderland, SR2 9HP
Czechia5 sites
Fakultni Nemocnice Ostrava
Ostrava-Poruba, 708 52
University hospital Kralovske Vinohrady
Prague, 10034
AXON Clinical, s.r.o.
Prague, 150 00
Vseobecna fakultni nemocnice v Praze
Prague, 2128 08
Gemini Eye Clinic
Zlín, 760 01
Poland5 sites
Eye Surgery Center Professor Zagorski
Bydgoszcz, 85-316
Oftalmika Eye Hospital
Bydgoszcz, 85-631
Grupo Laser Vision
Rzeszów, 35-017
Oculomedica Eye Centre
Tarnów, 33-100
UNO-MED Centrum Medyne
Tarnów, 33-100
Israel4 sites
Assaf ha Rofeh MC
Be’er Ya‘aqov, 7030000
Rambam Health Care Campus
Haifa, 3109601
Hadassah Medical Center
Jerusalem, 91120
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239
Canada3 sites
Ivey Eye Institute
London, Ontario, N6A 4V2
University of Ottawa Eye Institute
Ottawa, Ontario, K1H 8L6
Retina Centre of Ottawa
Ottawa, Ontario, K2B 7E9
Italy2 sites
IRCCS San Raffaele
Milan, 20132
ASST Fatebenefratelli-Sacco Ospedale Luigi Sacco
Milan, 20157
Netherlands2 sites
Academisch Medisch Centrum
Amsterdam, 1105 AZ
Radboud university medical center Oogheelkunde
Nijmegen, 6525 EX
New Zealand2 sites
Southern Eye Specialists
Christchurch, 8013
Hamilton Eye Clinic
Hamilton, 3204
Spain2 sites
Hospital Universitario Puerta de Hierro
Madrid, 28222
Instituto Oftalmologico Gomez-Ulla
Santiago de Compostela, 15706
About this study
Official title: A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).
- Being tested
- PEGCETACOPLAN (APL-2)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PEGCETACOPLAN (APL-2)Drug
Complement (C3) Inhibitor
| Study group | Role | What they receive |
|---|---|---|
| Monthly: Pegcetacoplan/ Pegcetacoplan | Experimental | Participants who received monthly intravitreal (IVT) pegcetacoplan (15 milligrams [mg]/100 microlitres [μL]) in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) continued to receive monthly IVT pegcetacoplan (15 mg/100 μL) for up to 36 months. Receives: Drug: PEGCETACOPLAN (APL-2) |
| EOM: Pegcetacoplan/Pegcetacoplan | Experimental | Participants who received IVT pegcetacoplan (15 mg/100 μL) every other month (EOM) in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) continued to receive IVT pegcetacoplan (15 mg/100 μL) EOM for up to 36 months. Receives: Drug: PEGCETACOPLAN (APL-2) |
| Monthly: Sham/Pegcetacoplan | Experimental | Participants who received sham monthly in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) received monthly IVT pegcetacoplan (15 mg/100 μL) for up to 36 months. Receives: Drug: PEGCETACOPLAN (APL-2) |
| EOM: Sham/Pegcetacoplan | Experimental | Participants who received sham EOM in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) received IVT pegcetacoplan (15 mg/100 μL) EOM for up to 36 months. Receives: Drug: PEGCETACOPLAN (APL-2) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Who Experienced at Least One Ocular and Systemic Adverse Events (AEs)
An AE is any untoward medical occurrence associated with use of a drug in humans, whether or not it is considered study drug-related. An AE can, therefore, be any unfavorable and unintended sign, including a clinically significant abnormal laboratory finding, symptom, or disease temporally associated with the use of an investigational product, whether considered related to the investigational product.
Measured: From Day 1 up to Month 36
Secondary outcomes (17)
Change From Baseline in Total Area of Geographic Atrophy (GA) Lesion(s) in the Study Eye
The change in GA lesion area was measured by a qualified central reading center based on fundus autofluorescence (FAF) images.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in the Rate of GA Lesion Growth in the Study Eye
The mean rate of change in GA area was analyzed by use of a piecewise linear mixed effect model assuming time as continuous and piecewise linear in FAS based on FAF images.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye
The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was >19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A negative change from baseline indicates loss in visual acuity.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in Low-Luminance Best-Corrected Visual Acuity (LL-BCVA) Score of the Study Eye
The LL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). It was measured by placing a neutral density trial lens causing a reduction of 2.0 log units in luminance. If the 4-meter score was >19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A negative change from baseline indicates loss in visual acuity.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in Monocular Maximum Corrected Reading Speed of the Study Eye
The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNRead) or Radner user manuals, with adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute was implemented. Maximum reading speed was calculated as the mean of the three highest nonzero reading speeds (or two, or one value, as available), except when all words per minute were calculated as 0: then the maximum reading speed was calculated as 0. A negative change from baseline indicated a decrease in the monocular reading speed; disease worsening.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in Binocular Maximum Corrected Reading Speed
The maximum reading speed was calculated per MNRead or Radner user manuals, with adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute was implemented. Maximum reading speed was calculated as the mean of the three highest nonzero reading speeds (or two, or one value, as available), except when all words per minute were calculated as 0: then the maximum reading speed was calculated as 0. A negative change from baseline indicated a decrease in the binocular reading speed; disease worsening.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in Number of Scotomatous Points of the Study Eye
The number of absolute scotomatous points was determined from mesopic microperimetry as an assessment of the macular functional response.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in Macular Sensitivity of the Study Eye
Macular sensitivity was assessed by mesopic microperimetry. A negative change from baseline indicates a decrease in the macular sensitivity.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in 95% Bivariate Contour Ellipse Area (BCEA) Degrees Squared (Deg²) of the Study Eye
Microperimetry was conducted to assess the bivariate contour ellipse area 95%.
Measured: Baseline, Months 12, 24 and 36
Mean Change From Baseline in Functional Reading Independence (FRI) Index Score
The FRI index is an individualized assessment of functional reading independence. The questionnaire has 7 items with one total index score. Scores derived from the index range from 1 (unable to do independently) to 4 (total independence) with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI; disease worsening. Least squares mean was calculated using a mixed effect model for repeated measure (MMRM) model.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-Item Version (NEI VFQ-25) Composite Score
The NEI-VFQ-25 is an interviewer-administered questionnaire designed to assess participant-reported visual function. It is a 25-item questionnaire with a composite score and covers 12 domains of functional health status and well-being (general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, and peripheral vision). Scoring yields 12 subscales based on the 12 domains covered in the questionnaire. These scales are scored from 0 to 100 with higher scores indicating better visual function. A composite score is the average of the vision-targeted sub-scale scores, excluding the general health rating question. A negative change from baseline indicated a decrease in visual functioning; disease worsening.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in NEI VFQ-25 Near Activity Subscale Score
The NEI-VFQ-25 is an interviewer-administered questionnaire designed to assess participant-reported visual function. It is a 25-item questionnaire with a composite score and covers 12 domains of functional health status and well-being (general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, and peripheral vision). Scoring yields 12 subscales based on the 12 domains covered in the questionnaire. The possible score range is 0 to 100 with higher scores indicating better visual function. A negative change from baseline indicated a decrease in visual functioning; disease worsening. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
Measured: Baseline, Months 12, 24 and 36
Change From APL2-GA-305 Baseline in NEI VFQ-25 Distance Activity Subscale Score
The NEI-VFQ-25 is a 25-item questionnaire with a composite score and covers 12 domains of functional health status and well-being. A distance activity subscale score one of the domains is the average of 3 items: 8 (How much difficulty do you have reading street signs or the names of stores?), 9 (Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?) and 14 (Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?). The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated a decrease in visual functioning; disease worsening.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in NEI VFQ-25 Driving Subscale Score
The NEI-VFQ-25 is a 25-item questionnaire with a composite score and covers 12 domains of functional health status and well-being. A driving subscale score one of the domains is the average of 3 items: 15c (If currently driving: How much difficulty do you have driving during the day time in familiar places?), 16 (How much difficulty do you have driving at night), and 16a (How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic?). The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated a decrease in visual functioning; disease worsening.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in National Eye Institute Visual Functioning Questionnaire 39-Item Version (NEI VFQ-39) Composite Score
NEI-VFQ-25 includes 13 additional items under 7 subscales related to general health, general vision, near vision, distance vision, social function, driving, role limitations, well-being or distress and dependency that allow for the calculation of NEI-VFQ-39 scores. The NEI-VFQ composite score is obtained by averaging the vision-related subscales, excluding the general health rating question. The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated a decrease in visual functioning; disease worsening.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in NEI VFQ-39 Near Activity Subscale Score
NEI-VFQ-25 includes 13 additional items under 7 subscales, enabling calculation of NEI-VFQ-39 scores. NEI-VFQ near activity subscale score is obtained by averaging 6 items: 5 (How much difficulty do you have reading ordinary print in newspapers), 6 (How much difficulty do you have doing work/hobbies that require you to see up close?), 7 (Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?), A3 (Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on medicine bottle, or on legal forms?), A4 (Because of your eyesight, how much difficulty do you have figuring out bills you receive are accurate?) \& A5 (Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair or putting on makeup). The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated reduced visual functioning; disease worsening.
Measured: Baseline, Months 12, 24 and 36
Change From Baseline in NEI VFQ-39 Distance Activity Subscale Score
NEI-VFQ-25 includes 13 additional items under 7 subscales, enabling calculation of NEI-VFQ-39 scores. NEI-VFQ near activity subscale score is obtained by averaging 6 items: 8 (How much difficulty do you have reading street signs/names of stores?), 9 (Because of your eyesight, how much difficulty do you have going down steps, stairs/ curbs in dim light/ at night?) and 14 (Because of your eyesight, how much difficulty do you have going out to see movies, plays/sports events?), A6 (Because of your eyesight, how much difficulty do you have recognizing people you know from across a room?), A7 (Because of your eyesight, how much difficulty do you have taking part in active sports/other outdoor activities?) \& A8 (Because of your eyesight, how much difficulty do you have seeing \& enjoying programs on TV?). The possible score range is 0 to 100, with higher scores indicating better visual function. A negative change from baseline indicated reduced visual functioning; disease worsening.
Measured: Baseline, Months 12, 24 and 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2021
- Study start4 Mar 2021
- Primary completion5 Sep 2025
- Study completion5 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Geographic Atrophy Secondary to Age-related Macular DegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 792 participants (actual)
Sponsor and investigators
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04770545
- Sponsor's protocol ID
- APL2-GA-305
- Acronym
- GALE
- Status last verified
- Oct 2026
- First submitted
- 23 Feb 2021
- Last updated
- 28 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- ClinicalTrials.gov ID
- NCT04770545
- Acronym / sponsor ID
- GALE / APL2-GA-305
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 792 participants (actual)
- Lead sponsor
- Apellis Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- 4 Mar 2021 (actual)
- Primary completion
- 5 Sep 2025 (actual)
- Study completion
- 5 Sep 2025 (actual)
- First posted
- 25 Feb 2021 (actual)
- Results
- Posted 28 Oct 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Monthly: Pegcetacoplan/ Pegcetacoplan | Experimental | Drug: PEGCETACOPLAN (APL-2)Participants who received monthly intravitreal (IVT) pegcetacoplan (15 milligrams [mg]/100 microlitres [μL]) in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) continued to receive monthly IVT pegcetacoplan (15 mg/100 μL) for up to 36 months. |
| EOM: Pegcetacoplan/Pegcetacoplan | Experimental | Drug: PEGCETACOPLAN (APL-2)Participants who received IVT pegcetacoplan (15 mg/100 μL) every other month (EOM) in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) continued to receive IVT pegcetacoplan (15 mg/100 μL) EOM for up to 36 months. |
| Monthly: Sham/Pegcetacoplan | Experimental | Drug: PEGCETACOPLAN (APL-2)Participants who received sham monthly in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) received monthly IVT pegcetacoplan (15 mg/100 μL) for up to 36 months. |
| EOM: Sham/Pegcetacoplan | Experimental | Drug: PEGCETACOPLAN (APL-2)Participants who received sham EOM in the antecedent studies (APL2-103 [NCT03777332], APL2-303 [NCT03525600], and APL2-304 [NCT03525613]) received IVT pegcetacoplan (15 mg/100 μL) EOM for up to 36 months. |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Ocular-specific inclusion criteria apply to the study eye only.
- Subjects must have participated in APL2-103 (NCT03777332) or completed the treatment at Month 24 of either APL2-303 (Derby, NCT03525613) or APL2-304 (Oaks, NCT03525600).
- For subjects who participated in either the 303 or 304 studies, the condition listed below must also be met for participating in this study.
- The eyes of subjects must have transparency to permit visualization of parts inside the eye such as the retina and subjects must be able to look steadily at a provided target allowing the doctor to get good quality pictures from the eye.
Key exclusion criteria (7 listed)
- Subjects cannot take part in the study if the eye that will be treated during the study currently meets any of the following conditions:
- Participants in APL2 303/304 studies who fully stopped study drug treatment before the visit in month 24 but remain in the study to observe the study medication's safety. Those subjects who temporarily paused study drug treatment are still eligible to participate.
- If, according to your doctor you currently have any disease affecting your eyes that could interfere with your vision, including diseases that affect your retina or macula (the center of the back of your eyes). And, if according to your doctor, the disease in your eyes is benign and does not interfere with the study (e.g. diseases that affects the periphery of the retina), you are also eligible to take part in the study.
- If, according to your doctor you currently have any inflammation/infection in or around your eyes that could prohibit you from receiving an injection inside your eyes.
- If, according to your doctor, any current disease that could directly interfere in your participation in the study or that could make it difficult for you to come to the scheduled visits during the next three years over the next 36 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PEGCETACOPLAN (APL-2)Complement (C3) Inhibitor | Drug | EOM: Pegcetacoplan/Pegcetacoplan, EOM: Sham/Pegcetacoplan, Monthly: Pegcetacoplan/ Pegcetacoplan, Monthly: Sham/Pegcetacoplan |
Primary outcome
Number of Participants Who Experienced at Least One Ocular and Systemic Adverse Events (AEs)
Time frame: From Day 1 up to Month 36
An AE is any untoward medical occurrence associated with use of a drug in humans, whether or not it is considered study drug-related. An AE can, therefore, be any unfavorable and unintended sign, including a clinically significant abnormal laboratory finding, symptom, or disease temporally associated with the use of an investigational product, whether considered related to the investigational product.
17 secondary outcomes
Change From Baseline in Total Area of Geographic Atrophy (GA) Lesion(s) in the Study Eye
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in the Rate of GA Lesion Growth in the Study Eye
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in Low-Luminance Best-Corrected Visual Acuity (LL-BCVA) Score of the Study Eye
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in Monocular Maximum Corrected Reading Speed of the Study Eye
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in Binocular Maximum Corrected Reading Speed
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in Number of Scotomatous Points of the Study Eye
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in Macular Sensitivity of the Study Eye
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in 95% Bivariate Contour Ellipse Area (BCEA) Degrees Squared (Deg²) of the Study Eye
Time frame: Baseline, Months 12, 24 and 36
Mean Change From Baseline in Functional Reading Independence (FRI) Index Score
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-Item Version (NEI VFQ-25) Composite Score
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in NEI VFQ-25 Near Activity Subscale Score
Time frame: Baseline, Months 12, 24 and 36
Change From APL2-GA-305 Baseline in NEI VFQ-25 Distance Activity Subscale Score
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in NEI VFQ-25 Driving Subscale Score
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in National Eye Institute Visual Functioning Questionnaire 39-Item Version (NEI VFQ-39) Composite Score
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in NEI VFQ-39 Near Activity Subscale Score
Time frame: Baseline, Months 12, 24 and 36
Change From Baseline in NEI VFQ-39 Distance Activity Subscale Score
Time frame: Baseline, Months 12, 24 and 36
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Geographic Atrophy Secondary to Age-related Macular Degeneration
Active, not recruitingObservational study
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic Atrophy, Macular Degeneration
RecruitingPhase 2
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Geographic Atrophy Secondary to Age-Related Macular Degeneration
RecruitingPhase 2
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Geographic Atrophy of the Macula
RecruitingPhase 1/2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy
RecruitingPhase 1/2
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Geographic Atrophy Secondary to Age-related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
175 sites in 15 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing PEGCETACOPLAN (APL-2) in people with Geographic Atrophy Secondary to Age-related Macular Degeneration, run by Apellis Pharmaceuticals, Inc. at 175 sites in 15 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 175 sites in United States, France, Germany, Argentina, Australia and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 28 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants Who Experienced at Least One Ocular and Systemic Adverse Events (AEs) (time frame: From Day 1 up to Month 36). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.